The list price for a two-pack of the pens is $608, up about 500 percent in a decade. But Heather Bresch, Mylan's chief executive, stayed firm in her message that the list price of EpiPen had increased because of the inherent complexity of the pharmaceutical marketplace and that few patients were paying the list price. But lawmakers were clearly frustrated as they struggled to understand how much total profit the company had made and how that had changed as the list price increased. attempted to break down how much of the $912 million in EpiPen net revenue for Mylan in 2015 represented profit. Correction: A previous version of this story misstated the profit Mylan makes on EpiPen.

Source: Washington Post September 21, 2016 19:12 UTC